Want to see AU:ILA full AI Analyst Report?
ILA Stock Chart & Stats
AU$0.40
<AU$0.01(1.25%)
At close: 4:00 PM EDT
AU$0.40
<AU$0.01(1.25%)
Day’s Range― - ―
52-Week RangeAU$0.16 - AU$0.63
Previous CloseN/A
Volume241.31K
Average Volume (3M)781.24K
Market Cap
AU$115.41M
Enterprise ValueAU$84.40M
Total Cash (Recent Filing)AU$6.87M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta-0.99
Next Earnings
Aug 27, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding295,916,700
10 Day Avg. Volume388,484
30 Day Avg. Volume781,243
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)3.39
Price to Sales (P/S)204.10
P/FCF Ratio-8.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetZero reported debt and materially higher equity give the company durable solvency and financing optionality. For an R&D-heavy biotech this reduces bankruptcy risk, preserves strategic flexibility to raise capital on better terms, and supports continued investment in trials and development.
Focused Antiviral R&D PipelineA concentrated pipeline targeting mosquito-borne viruses provides a clear strategic niche and specialization. That focus can create durable scientific expertise, clearer regulatory development paths and make the company a more attractive partner or acquisition target for larger pharma pursuing infectious-disease franchises.
Prior Revenue Step-up Indicates CapacityA prior increase in revenue suggests the company has demonstrated some ability to monetize assets or capture milestone/contract income. While volatile, historical revenue growth indicates a non-zero commercial or partnership pathway that could be leveraged if development progress or collaborations resume.
Bears Say
Revenue Collapse & VolatilityA ~70% revenue decline in 2025 combined with a multi-million dollar net loss signals weak or inconsistent commercial traction. Durably low and volatile revenue undermines internal funding of R&D, raises dependency on external financing, and makes long-term planning and program continuity more uncertain.
Ongoing Cash BurnSustained negative operating cash flow reflects structural cash burn to fund development activities. Even with zero debt, continued negative OCF forces reliance on equity issuances or partnerships, increasing dilution risk and possibly constraining the timing and scope of clinical programs over the medium term.
Negative Profitability & ReturnsDeep negative margins and persistent losses translate into negative returns on equity and limited internal reinvestment capacity. Over a multi-month horizon, this weak profitability increases funding pressure, heightens dilution risk, and limits the company's ability to scale operations without significant external support.
Island Pharmaceuticals Ltd News
ILA FAQ
What was Island Pharmaceuticals Ltd’s price range in the past 12 months?
Island Pharmaceuticals Ltd lowest share price was AU$0.16 and its highest was AU$0.63 in the past 12 months.
What is Island Pharmaceuticals Ltd’s market cap?
Island Pharmaceuticals Ltd’s market cap is AU$115.41M.
When is Island Pharmaceuticals Ltd’s upcoming earnings report date?
Island Pharmaceuticals Ltd’s upcoming earnings report date is Aug 27, 2026 which is in 25 days.
How were Island Pharmaceuticals Ltd’s earnings last quarter?
Island Pharmaceuticals Ltd released its earnings results on Feb 25, 2026. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of -AU$0.005 by -AU$0.014.
Is Island Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Island Pharmaceuticals Ltd’s price is currently Overvalued.
Does Island Pharmaceuticals Ltd pay dividends?
Island Pharmaceuticals Ltd does not currently pay dividends.
What is Island Pharmaceuticals Ltd’s EPS estimate?
Island Pharmaceuticals Ltd’s EPS estimate is -0.01.
How many shares outstanding does Island Pharmaceuticals Ltd have?
Island Pharmaceuticals Ltd has 295,916,700 shares outstanding.
What happened to Island Pharmaceuticals Ltd’s price movement after its last earnings report?
Island Pharmaceuticals Ltd reported an EPS of -AU$0.019 in its last earnings report, missing expectations of -AU$0.005. Following the earnings report the stock price went up 1.408%.
Which hedge fund is a major shareholder of Island Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in AU:ILA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Island Pharmaceuticals Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ILA Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
86.01%
Trailing 12-Months
Company Description
Island Pharmaceuticals Ltd
Island Pharmaceuticals Limited functions as a pharmaceutical enterprise dedicated to drug discovery and repurposing, with a specific focus on creating preventative or therapeutic solutions for viral infections. Its lead therapeutic agent, ISLA-101, is currently under development for both preventing and treating dengue fever and other illnesses transmitted by mosquitoes. The company participates in various strategic collaborations, including a research partnership with Monash University to evaluate known molecules against host targets, and a research and development alliance with Griffith University aimed at screening for active antiviral compounds through a systematic repurposing approach. Additionally, Island Pharmaceuticals has a research agreement with Compounds Australia, providing access to an extensive drug library containing roughly 4,500 molecules for potential drug repurposing and pipeline enhancement. In anticipation of its ISLA-101 Phase II clinical study, the company has also established a cooperative research and development pact with the U.S. Army. Other key agreements include a supply contract with Catalent for the production of Fenretinide softgels for individuals participating in dengue fever trials, and the entitlement to reference the National Cancer Institute's Investigational New Drug (IND) application for ISLA-101. The company, founded in 2017, is based in Camberwell, Australia.
Technical Analysis
Actinogen Medical
―
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―